Last reviewed · How we verify

NCT05610917

Community-based Rehabilitation Management for Patients With Remitted Geriatric Depression

Status unknown EARLY_PHASE1 Last updated 9 November 2022
What this trial tests

EARLY_PHASE1 trial testing CBRM (community-based rehabilitation management) in Geriatric Depression in 120 participants. Status unknown.

Timeline
1 January 2023
Primary endpoint
1 January 2024
1 January 2026

Quick facts

Lead sponsorDuan Li
PhaseEARLY_PHASE1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeprevention
Enrollment120
Start date1 January 2023
Primary completion1 January 2024
Estimated completion1 January 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Duan Li

Who can join

60 and older, any sex, with Geriatric Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study intends to take patients with RGD as objects. Further construct a community-based rehabilitation management (CBRM) program with drug treatment, rehabilitation measures of education, psychology and exercise as its core content on the basis of evidence-based practice approach. Based on the cost-utility analysis of health economics, the health and economic benefits of the CBRM program will be evaluated, and a theoretical reference will be provided for community health institutions to carry out whole-course rehabilitation management practice and health policy formulation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Geriatric Depression

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05610917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing